Search Results - "CREMER, F. W"

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield by BREITKREUTZ, I, LOKHORST, H. M, SALWENDER, H, HAENE, A, SONNEVELD, P, COLDSCHMIDT, H, RAAB, M. S, VAN DER HOLT, B, CREMER, F. W, HERRMANN, D, GLASMACHER, A, SCHMIDT-WOLF, I. G. H, BLAU, I. W, MARTIN, H

“…In a phase III randomized, multicenter study, the German-speaking Myeloma-Multicenter Group (GMMG) and the Dutch-Belgian Hemato-Oncology Cooperative Group…”
Get full text

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma by MAHTOUK, K, CREMER, F. W, QUITTET, P, GOLDSCHMIDT, H, ROSSI, J.-F, HOSE, D, KLEIN, B, REME, T, JOURDAN, M, BAUDARD, M, MOREAUX, J, REQUIRAND, G, FIOL, G, DE VOS, J, MOOS, M

“…The epidermal growth factor (EGF)/EGF-receptor (ErbB1-4) family is involved in the biology of multiple myeloma (MM). In particular, ErbB-specific inhibitors…”
Get full text

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14) by HUNDEMER, M, KLEIN, U, GOLDSCHMIDT, H, HOSE, D, RAAB, M.-S, CREMER, F. W, JAUCH, A, BENNER, A, HEISS, C, MOOS, M, HO, A. D

“…Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of…”
Get full text

Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes by Kratz, C P, Franke, L, Peters, H, Kohlschmidt, N, Kazmierczak, B, Finckh, U, Bier, A, Eichhorn, B, Blank, C, Kraus, C, Kohlhase, J, Pauli, S, Wildhardt, G, Kutsche, K, Auber, B, Christmann, A, Bachmann, N, Mitter, D, Cremer, F W, Mayer, K, Daumer-Haas, C, Nevinny-Stickel-Hinzpeter, C, Oeffner, F, Schlüter, G, Gencik, M, Überlacker, B, Lissewski, C, Schanze, I, Greene, M H, Spix, C, Zenker, M

“…Background: Somatic mutations affecting components of the Ras-MAPK pathway are a common feature of cancer, whereas germline Ras pathway mutations cause…”
Get full text

Preoperative elevation of serum C - reactive protein is predictive for prognosis in myeloma bone disease after surgery by ZAHLTEN-HINGURANAGE, A, GOLDSCHMIDT, H, CREMER, F. W, EGERER, G, MOEHLER, T, WITTE, D, BERND, L, SABO, D, ZEIFANG, F

“…We investigated whether preoperative levels of serum C-reactive protein (CRP) and its correlation with tumour clinicopathological findings adds prognostic…”
Get full text

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients by GOLDSCHMIDT, H, SONNEVELD, P, HOELZER, D, HO, A. D, LOKHORST, H. M, CREMER, F. W, VAN DER HOLT, B, WESTVEER, P, BREITKREUTZ, I, BENNER, A, GLASMACHER, A, SCHMIDT-WOLF, I. G. D, MARTIN, H

Get full text

Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation by LIPINSKI, E, CREMER, F. W, HO, A. D, GOLDSCHMIDT, H, MOOS, M

“…The clinical relevance of the assessment of minimal residual disease (MRD) in patients with multiple myeloma (MM) to predict disease recurrence has not been…”
Get full text

Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation by GEMMEL, C, CREMER, F. W, WEIS, M, WITZENS, M, MOLDENHAUER, G, KONICZEK, K.-H, IMBACH, U, HO, A. D, MOOS, M, GOLDSCHMIDT, H

“…In multiple myeloma (MM), circulating malignant B cells are proposed as the proliferative compartment of the disease. In view of the close relationship between…”
Get full text

Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma by Raab, M. S., Cremer, F. W., Breitkreutz, I. N., Gerull, S., Luft, T., Benner, A., Goerner, M., Ho, A. D., Goldschmidt, H., Moos, M.

“…Background: Non-myeloablative allogeneic stem cell transplantation followed by immunomodulatory therapies is considered a potentially curative approach in the…”
Get full text

A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma by CREMER, F. W, KIEL, K, WALLMEIER, M, GOLDSCHMIDT, H, MOOS, M

“…High-dose chemotherapy (HDT) with autografting of hematopoietic stem cells induces up to 50% of complete remissions in patients with multiple myeloma. Cases of…”
Get full text

Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma by CREMER, F. W, EHRBRECHT, E, KIEL, K, BENNER, A, HEGENBART, U, HO, A. D, GOLDSCHMIDT, H, MOOS, M

“…The aim of this investigation was to examine the possible clinical significance of the kinetics of bone marrow (BM) tumor load during the course of sequential…”
Get full text

Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation by KIEL, K, CREMER, F. W, ROTTENBURGER, C, KALLMEYER, C, EHRBRECHT, E, ATZBERGER, A, HEGENBART, U, GOLDSCHMIDT, H, MOOS, M

“…In multiple myeloma (MM) circulating CD19+ cells have been considered as myeloma precursors. As these cells are also possibly a reservoir of treatment…”
Get full text

First and second apheresis in patients with multiple myeloma : no differences in tumor load and hematopoietic stem cell yield by KIEL, K, CREMER, F. W, EHRBRECHT, E, WALLMEIER, M, HEGENBART, U, GOLDSCHMIDT, H, MOOS, M

“…Autologous peripheral blood stem cells (PBSC) are now widely used to support myeloablative therapy in patients with multiple myeloma (MM). The presence of…”
Get full text

Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content by Voso, Maria Teresa, Hohaus, Stefan, Moos, Marion, Pförsich, Margit, Cremer, Friedrich W., Schlenk, Richard F., Martin, Simona, Hegenbart, Ute, Goldschmidt, Hartmut, Haas, Rainer

“…The efficacy of an immunomagnetic purging method and the Isolex 300 devices were assessed for selecting CD34+ cells from leukapheresis products of 29 patients…”
Get full text

Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high‐dose therapy and peripheral blood stem cell transplantation by Rottenburger, Christof, Kiel, Katja, Bösing, Tobias, Cremer, Friedrich W., Moldenhauer, Gerhard, Ho, Anthony D., Goldschmidt, Hartmut, Moos, Marion

“…The number of circulating clonotypic B cells in patients with multiple myeloma (MM) after high‐dose therapy (HDT) with peripheral blood stem cell…”
Get full text

Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone by Cremer, F W, Kiel, K, Wallmeier, M, Haas, R, Goldschmidt, H, Moos, M

“…High-dose therapy with autografting of peripheral blood stem cells (PBSCs) has become an accepted treatment modality. However, gene-marking studies in patients…”
Get more information

Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G‐CSF do not bear Kaposi's sarcoma associated herpesvirus DNA by Bellos, Frauke, Cremer, Friedrich W., Ehrbrecht, Edith, Goldschmidt, Hartmut, Moos, Marion

“…The presence of Kaposi's sarcoma associated herpesvirus (KSHV) in bone marrow dendritic cells, in bone marrow biopsies and in dendritic cells of peripheral…”
Get full text

A 439 kb-sized homozygous deletion in 17p13.3 leading to biallelic loss of the ASPA as cause of Canavan disease detected by SNP-array analysis by Caliebe, A., Vater, I., Plendl, H., Gesk, S., Siebert, R., Cremer, F.W., Klein-Hitpass, L.

Get full text

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy by Minnema, M C, Breitkreutz, I, Auwerda, J J A, van der Holt, B, Cremer, F W, van Marion, A M W, Westveer, P H M, Sonneveld, P, Goldschmidt, H, Lokhorst, H M

Get full text

A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells by Cremer, F W, Kiel, K, Sucker, C, Wacker, J, Atzberger, A, Haas, R, Goldschmidt, H, Moos, M

“…In multiple myeloma (MM), the presence of tumor cells in leukapheresis products (LP) has been demonstrated with highly sensitive molecular biological tools in…”
Get full text